Reference Document Containing The Annual Financial Report

Overview

The report describes the 2014 merger of BioAlliance Pharma and Topotarget that created Onxeo and expanded its orphan-oncology portfolio. The company obtained US marketing authorization for Beleodaq and launched the product with Spectrum Pharmaceuticals. It also reported positive preliminary Phase II results for Validive and completed a major capital increase to support development of its key programs.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2014
Period: 1 January 2014 – 31 December 2014
Publication date: 14 April 2015
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services